获取途径

作者

L. Li J. Zheng Z. Liu Y. Huang J. Xiao S. Wang Q. Yu Q. Zhang X. Hu W. Zhao W. Hou F.-M. Kong J. Yu S. Yuan

作者单位

²Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China ⁴Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China ⁵Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China ¹Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China ³Department of Oncology, Zibo Forth People's Hospital, Zibo, Shandong, China ⁶Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China

刊名

Clinical Oncology

年份

2022

卷号

Vol.34 No.6

页码

e238-e245

ISSN

0936-6555

关键词

¹⁸F-RGD adverse events antiangiogenic functional imaging integrin αvβ3 PET/CT

摘要

Aims The adverse events during antiangiogenic therapy inevitably influence a patient's quality of life. Therefore, biomarkers to identify patients who will experience adverse events would be very valuable in treatment planning. Materials and methods Between September 2016 and December 2019, patients scheduled for single-agent apatinib were prospectively enrolled and underwent F-RGD positron emission tomography/computed tomography pre-treatment. Maximum and mean standard uptake values were o...更多

Aims The adverse events during antiangiogenic therapy inevitably influence a patient's quality of life. Therefore, biomarkers to identify patients who will experience adverse events would be very valuable in treatment planning. Materials and methods Between September 2016 and December 2019, patients scheduled for single-agent apatinib were prospectively enrolled and underwent F-RGD positron emission tomography/computed tomography pre-treatment. Maximum and mean standard uptake values were obtained from thyroid, liver, gastric cardia, gastric body, gastric pylorus and spleen. Statistical methods included the independent sample t-test, Mann-Whitney U-test, receiver operating characteristic curve analysis and chi-squared test. Results In total, 60 patients were initially screened and consented for F-RGD PET/CT scans. The three most frequent adverse events were fatigue , hypertension and nausea , accounting for 72% in the 50 patients included in the analysis. SUV and SUV of thyroid and liver were significantly associated with fatigue, whereas SUV and SUV of thyroid and spleen were significantly associated with hypertension and SUV and SUV of thyroid and gastric cardia were significantly associated with nausea , SUV for hypertension and SUV for nausea . Classified by the cut-off values for SUV , SUV and SUV , patients with low RGD SUV in liver, spleen and gastric cardia had statistically higher incidence of fatigue , hypertension and nausea . Conclusions Low pre-treatment F-RGD uptake in the liver, spleen and gastric cardia were predictive of the adverse events fatigue, hypertension and nausea during apatinib treatment, respectively.收起

文献类型

期刊

浏览量

16